Mamedica Limited

Mamedica Limited, located in the UK, specializes in providing medical cannabis solutions aimed at alleviating a range of chronic conditions, including anxiety, chronic pain, and arthritis. Founded in 2021, Mamedica Limited is based in London, UK, offering medical cannabis solutions. The company has engaged in one investment deal, raising GBP 4. 5 million in venture funding on September 14, 2025, led by Casa Verde Capital.

The founder’s background is not specified, but the company has not undergone significant pivots or changes in strategy since its inception. Mamedica focuses on medical cannabis solutions tailored for chronic conditions such as anxiety, chronic pain, and arthritis. Their product offerings include dried cannabis flower, cannabis oil extracts, discreet vapor cartridges, flavored pastilles, and odourless capsules, all aimed at providing effective symptom relief to patients across the UK who seek alternative treatments. Mamedica operates on a fee-for-service model, charging GBP 150 for initial consultations and GBP 75 for follow-ups.

The company offers a one-time Access Scheme fee of GBP 200, covering lifetime clinic access for veterans, students, and benefit recipients. Patients receive their prescribed cannabis products typically within 24 hours of consultation, emphasizing seamless access to care. In September 2025, Mamedica Limited raised GBP 4. 5 million in funding, which will be utilized to enhance service capacity and develop new treatment programs.

The company is also focusing on expanding its reach within the UK market, though specific new products or geographical areas targeted for growth have not been disclosed.